Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CHAN17022 / EA3132 / Ronald Maggiore

Research Question:
Do the changes in a gene called TP53 influence the response to radiation therapy alone or radiation therapy in combination with cisplatin chemotherapy?

Basic Study Information

Purpose:
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell carcinoma of the head and neck.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02734537?term=ea3132&rank=1
Study Reference #: CHAN17022

Lead Researcher (Principal Investigator)

Lead Researcher:  Ronald Maggiore

Study Contact Information

Study Coordinator: Nichole Ransom
Phone: +1 585-276-8747
Email: nichole_ransom@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Squamous Cell

Return to Search